


## Data Sheet

<b>Product Name:</b>	Cridanimod
<b>Cat. No.:</b>	CS-W012606
<b>CAS No.:</b>	38609-97-1
<b>Molecular Formula:</b>	C <sub>15</sub> H <sub>11</sub> NO <sub>3</sub>
<b>Molecular Weight:</b>	253.26
<b>Target:</b>	IFNAR; Progesterone Receptor
<b>Pathway:</b>	Immunology/Inflammation; Others
<b>Solubility:</b>	H <sub>2</sub> O : < 0.1 mg/mL (insoluble); DMSO : 125 mg/mL (493.56 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

Cridanimod is a potent **progesterone receptor (PR)** activator mediated through induction of **IFN $\alpha$**  and **IFN $\beta$**  expression. Cridanimod is a small-molecule immunomodulator and interferon inducer<sup>[1][2]</sup>. IC<sub>50</sub> & Target: PR, IFN $\alpha$ , IFN $\beta$ <sup>[1]</sup> **In Vivo:** Cridanimod (IM; 1-6 mg; twice a week) has a significantly longer survival time. Cridanimod significant increases in IFN $\alpha$  and - $\beta$  in cridanimod-treated mice in a dose-dependent manner<sup>[1]</sup>.

### References:

[1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016

[2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.

### CAIndexNames:

10(9H)-Acridineacetic acid, 9-oxo-

### SMILES:

O=C(O)CN(C1=C2C=CC=C1)C3=CC=CC=C3C2=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA